S&P 500   4,603.22 (+0.38%)
DOW   36,238.26 (+0.33%)
QQQ   392.09 (+0.43%)
AAPL   195.64 (+0.71%)
MSFT   373.58 (+0.71%)
META   331.72 (+1.57%)
GOOGL   134.98 (-1.42%)
AMZN   147.50 (+0.42%)
TSLA   243.91 (+0.52%)
NVDA   476.39 (+2.24%)
NIO   7.40 (-1.20%)
BABA   72.24 (-0.12%)
AMD   128.77 (+0.31%)
T   16.86 (-1.35%)
F   11.04 (+2.03%)
MU   75.16 (+2.05%)
CGC   0.79 (+9.34%)
GE   120.36 (+0.74%)
DIS   92.81 (+0.50%)
AMC   6.94 (+1.76%)
PFE   28.89 (+0.91%)
PYPL   58.94 (+0.79%)
XOM   99.35 (+0.94%)
S&P 500   4,603.22 (+0.38%)
DOW   36,238.26 (+0.33%)
QQQ   392.09 (+0.43%)
AAPL   195.64 (+0.71%)
MSFT   373.58 (+0.71%)
META   331.72 (+1.57%)
GOOGL   134.98 (-1.42%)
AMZN   147.50 (+0.42%)
TSLA   243.91 (+0.52%)
NVDA   476.39 (+2.24%)
NIO   7.40 (-1.20%)
BABA   72.24 (-0.12%)
AMD   128.77 (+0.31%)
T   16.86 (-1.35%)
F   11.04 (+2.03%)
MU   75.16 (+2.05%)
CGC   0.79 (+9.34%)
GE   120.36 (+0.74%)
DIS   92.81 (+0.50%)
AMC   6.94 (+1.76%)
PFE   28.89 (+0.91%)
PYPL   58.94 (+0.79%)
XOM   99.35 (+0.94%)
S&P 500   4,603.22 (+0.38%)
DOW   36,238.26 (+0.33%)
QQQ   392.09 (+0.43%)
AAPL   195.64 (+0.71%)
MSFT   373.58 (+0.71%)
META   331.72 (+1.57%)
GOOGL   134.98 (-1.42%)
AMZN   147.50 (+0.42%)
TSLA   243.91 (+0.52%)
NVDA   476.39 (+2.24%)
NIO   7.40 (-1.20%)
BABA   72.24 (-0.12%)
AMD   128.77 (+0.31%)
T   16.86 (-1.35%)
F   11.04 (+2.03%)
MU   75.16 (+2.05%)
CGC   0.79 (+9.34%)
GE   120.36 (+0.74%)
DIS   92.81 (+0.50%)
AMC   6.94 (+1.76%)
PFE   28.89 (+0.91%)
PYPL   58.94 (+0.79%)
XOM   99.35 (+0.94%)
S&P 500   4,603.22 (+0.38%)
DOW   36,238.26 (+0.33%)
QQQ   392.09 (+0.43%)
AAPL   195.64 (+0.71%)
MSFT   373.58 (+0.71%)
META   331.72 (+1.57%)
GOOGL   134.98 (-1.42%)
AMZN   147.50 (+0.42%)
TSLA   243.91 (+0.52%)
NVDA   476.39 (+2.24%)
NIO   7.40 (-1.20%)
BABA   72.24 (-0.12%)
AMD   128.77 (+0.31%)
T   16.86 (-1.35%)
F   11.04 (+2.03%)
MU   75.16 (+2.05%)
CGC   0.79 (+9.34%)
GE   120.36 (+0.74%)
DIS   92.81 (+0.50%)
AMC   6.94 (+1.76%)
PFE   28.89 (+0.91%)
PYPL   58.94 (+0.79%)
XOM   99.35 (+0.94%)

Walgreens Boots Alliance Stock Price, News & Analysis (NASDAQ:WBA)

$23.30
+0.39 (+1.70%)
(As of 02:34 PM ET)
Compare
Today's Range
$22.72
$23.42
50-Day Range
$19.94
$24.19
52-Week Range
$19.68
$42.29
Volume
10.53 million shs
Average Volume
9.32 million shs
Market Capitalization
$20.13 billion
P/E Ratio
N/A
Dividend Yield
8.24%
Price Target
$29.36

Walgreens Boots Alliance MarketRank™ Stock Analysis

Analyst Rating
Hold
2.10 Rating Score
Upside/​Downside
26.0% Upside
$29.36 Price Target
Short Interest
Bearish
7.28% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.98mentions of Walgreens Boots Alliance in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$20,450 Sold Last Quarter
Proj. Earnings Growth
9.28%
From $3.34 to $3.65 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.92 out of 5 stars

Retail/Wholesale Sector

10th out of 159 stocks

Drug Stores & Proprietary Stores Industry

1st out of 2 stocks


WBA stock logo

About Walgreens Boots Alliance Stock (NASDAQ:WBA)

Walgreens Boots Alliance Inc. is a world-renowned healthcare, pharmacy, and retailing company. Founded in 1901 by John Boot and Charles R. Walgreen, the company has grown to become a leader in the industry, operating in nine countries and providing access to healthcare services to millions of people around the world. Walgreens Boots Alliance operates through three main segments: U.S. Retail Pharmacy, International, and U.S. Healthcare.

The U.S. Retail Pharmacy segment includes the Walgreens business, which operates health and wellness services, retail drugstores, specialty and home delivery pharmacy services, and an equity method investment in AmerisourceBergen. Walgreens stores have locations in all 50 U.S. states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, offering access to consumer goods and services, pharmacy, photo department, and health and wellness services. Walgreens also operates online stores like Walgreens.com, Drugstore.com, VisionDirect.com, and Beauty.com.

The International segment consists of pharmacy-led health and beauty retail businesses outside the United States and a pharmaceutical wholesaling and distribution company in Germany. This segment includes the Boots brand, which has a history stretching back over 170 years in the United Kingdom, and stores in Ireland and Thailand with Boots franchise operations in the Middle East and Indonesia. The remainder of the division comprises Farmacias Ahumada (FASA) pharmacies in Chile and Benavides in Mexico. The Pharmaceutical Wholesale Division, including the Alliance Healthcare brand, supplied medicines and other healthcare products to more than 115,000  doctors, health centers,  pharmacies, and hospitals annually in eleven countries through 306 distribution centers. AmerisourceBergen purchased most of the Alliance Healthcare wholesale division in June 2021 for $6.275bn in cash.

The U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omnichannel experience across the care journey. This segment includes the operation of 334 VillageMD clinics, including 146 co-located clinics, 124 standalone clinics, and 64 affiliate clinics.

Walgreens Boots Alliance produces many brands, including Soltan and Botanics, Boots Pharmaceuticals, and Boots Laboratories, No. 7, that Alliance Boots and Walgreens sought to launch internationally following the first share purchase in 2012. These brands include the famous No. 7 beauty serums, developed in Nottingham, the UVA 5-star suncare protection by Soltan, and the Botanics range, developed in partnership with the Royal Botanic Gardens, Kew. Boots' brand range includes medicines, healthcare products, skincare, and many more. Walgreens also has a self-branded line of products called "Well at Walgreens."

For the fiscal year 2020, Walgreens Boots Alliance reported earnings of US$456 million. The reported revenue was US$139.5 billion, an increase of 2.5% over the previous fiscal cycle. As of 2022, Walgreens Boots Alliance is ranked #18 on the Fortune 500 rankings. The company pays a Quarterly dividend of $0.48, representing an annual dividend yield of 5.08%. Wall Street analysts consider Walgreens stock to be Undervalued. 

Walgreens Boots Alliance has 862,503,540 shares outstanding, and its market cap is currently $31.99B. The company’s EPS estimate is $1.12, and its most recent earnings report saw it beat expectations with an EPS of $1.16. Following the earnings report, the stock price went down -6.135%. Among the most significant hedge funds holding Walgreens Boots Alliance’s shares is Antipodes Partners Ltd., which owns shares valued at $58M.

Walgreens Boots Alliance is a global healthcare leader committed to providing high-quality services and products to its customers. The company’s innovative strategies have earned it a reputation as a reliable and reputable partner for healthcare providers and consumers. With its wide array of products and services, Walgreens Boots Alliance is well-positioned to continue growing and meeting the needs of its customers for years to come.

WBA Stock Price History

WBA Stock News Headlines

Teva Pharma is the way to play the re-rise of generic drugs (WBA)
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth
What's open and closed on Thanksgiving this year?
The holiday season is here, which means spending time with family on Thanksgiving and also, for millions of people, hunting for the best deals on Black Friday
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
4 high yields near 52-week lows worth looking at (WBA)
These stocks trading near 52-week lows provide high-yielding values for buy-and-hold investors; most are at or near their bottom and may rebound soon
3 value stocks you shouldn't let go of this quarter (WBA)
The market has created the perfect opportunity for you to have your cake and eat it too. These three value stocks will likely be portfolio residents soon
Why Walgreens Boots Alliance Shares Jumped 8.8% Today
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Walgreens: Outlook After CEO Tim Wentworth Took Office
Walgreens (WBA) Launches Rx Savings Finder Digital Tool
Get To Know a CareCentrix Nurse Coach
Walmart, Target and Walgreens have a second theft problem
Boots: one step closer to the block
See More Headlines
Receive WBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Walgreens Boots Alliance and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/12 Dividend
8/18/2023
Dividend Payable
9/12/2023
Last Earnings
10/12/2023
Ex-Dividend for 12/12 Dividend
11/13/2023
Today
12/08/2023
Dividend Payable
12/12/2023
Next Earnings (Confirmed)
1/04/2024
Fiscal Year End
8/31/2024

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
Drug Retail
Current Symbol
NASDAQ:WBA
CUSIP
93142210
Employees
331,000
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$29.36
High Stock Price Target
$45.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+28.3%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Net Income
$-3,080,000,000.00
Pretax Margin
-3.90%

Debt

Sales & Book Value

Annual Sales
$139.08 billion
Cash Flow
$7.27 per share
Book Value
$32.78 per share

Miscellaneous

Free Float
713,594,000
Market Cap
$19.78 billion
Optionable
Optionable
Beta
0.76

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Stefano Pessina (Age 82)
    Executive Chairman of the Board
    Comp: $111.25k
  • Ms. Ornella BarraMs. Ornella Barra (Age 70)
    Chief Operating Officer of International
    Comp: $3.11M
  • Mr. Timothy C. Wentworth (Age 63)
    CEO & Director
  • Mr. Manmohan Mahajan (Age 44)
    Senior VP & Interim Global CFO
  • Mr. Todd D. Heckman (Age 50)
    VP, Interim Global Controller & Chief Accounting Officer
  • Dr. Neal Joseph Sample Ph.D. (Age 48)
    Executive VP & Chief Information Officer
  • Mr. Gerald Gradwell (Age 55)
    Senior Vice President of Investor Relations
  • Ms. Danielle Carim Gray (Age 45)
    Executive VP & Global Chief Legal Officer
  • Ms. Beth A. Leonard
    Senior VP & Chief Communications Officer
  • Ms. Holly May (Age 40)
    Executive VP & Global Chief Human Resources Officer

Should I Buy Walgreens Boots Alliance Stock? WBA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Walgreens Boots Alliance was last updated on Sunday, December 3, 2023 at 4:30 PM.

Pros

Here are some ways that investors could benefit from investing in Walgreens Boots Alliance, Inc.:

  • Strong presence in the healthcare, pharmacy, and retail industry, operating in multiple countries.
  • Diversified business segments, including U.S. Retail Pharmacy, International, and U.S. Healthcare.
  • Offers a wide range of health and wellness products, beauty, personal care, and general merchandise.
  • Partnerships with VillageMD, Shields, and CareCentrix, providing value-based care and specialty pharmacy services.
  • Current stock price is trading at rock-bottom levels, potentially offering an attractive entry point for investors.

Cons

Investors should be bearish about investing in Walgreens Boots Alliance, Inc. for these reasons:

  • Recent mixed quarter results and lowered guidance, indicating potential challenges in the current economic environment.
  • Downward revision to the outlook due to factors such as inflation and high interest rates impacting consumer budgets.
  • Analysts' consensus figures for second-half earnings growth trending lower, potentially affecting the stock's performance.
  • Negative sentiment in the long-term outlook, as analysts hesitate to revise their forecasts for the next quarter or two.
  • Uncertainty surrounding consumer spending and its impact on the stock market's direction.














WBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Walgreens Boots Alliance stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Walgreens Boots Alliance in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WBA, but not buy additional shares or sell existing shares.
View WBA analyst ratings
or view top-rated stocks.

What is Walgreens Boots Alliance's stock price target for 2024?

10 analysts have issued 1 year price targets for Walgreens Boots Alliance's shares. Their WBA share price targets range from $21.00 to $45.00. On average, they predict the company's share price to reach $29.36 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price.
View analysts price targets for WBA
or view top-rated stocks among Wall Street analysts.

How have WBA shares performed in 2023?

Walgreens Boots Alliance's stock was trading at $37.36 at the beginning of the year. Since then, WBA stock has decreased by 37.6% and is now trading at $23.30.
View the best growth stocks for 2023 here
.

When is Walgreens Boots Alliance's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, January 4th 2024.
View our WBA earnings forecast
.

How were Walgreens Boots Alliance's earnings last quarter?

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) released its quarterly earnings results on Thursday, October, 12th. The pharmacy operator reported $0.67 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by $0.02. The pharmacy operator earned $35.42 billion during the quarter, compared to analysts' expectations of $34.81 billion. Walgreens Boots Alliance had a negative net margin of 2.21% and a positive trailing twelve-month return on equity of 12.31%. Walgreens Boots Alliance's revenue for the quarter was up 9.2% on a year-over-year basis. During the same period last year, the firm earned $0.80 earnings per share.
Read the conference call transcript
.

How often does Walgreens Boots Alliance pay dividends? What is the dividend yield for Walgreens Boots Alliance?

Walgreens Boots Alliance announced a quarterly dividend on Thursday, October 26th. Stockholders of record on Tuesday, November 14th will be given a dividend of $0.48 per share on Tuesday, December 12th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 8.24%. The ex-dividend date is Monday, November 13th.
Read our dividend analysis for WBA
.

Is Walgreens Boots Alliance a good dividend stock?

Walgreens Boots Alliance (NASDAQ:WBA) pays an annual dividend of $1.92 per share and currently has a dividend yield of 9.24%. WBA has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for WBA.

What guidance has Walgreens Boots Alliance issued on next quarter's earnings?

Walgreens Boots Alliance issued an update on its FY 2024 earnings guidance on Thursday, October, 12th. The company provided earnings per share (EPS) guidance of $3.20-$3.50 for the period, compared to the consensus EPS estimate of $3.41. The company issued revenue guidance of $141.00 billion-$145.00 billion, compared to the consensus revenue estimate of $144.36 billion.

What is Stefano Pessina's approval rating as Walgreens Boots Alliance's CEO?

4,267 employees have rated Walgreens Boots Alliance Chief Executive Officer Stefano Pessina on Glassdoor.com. Stefano Pessina has an approval rating of 32% among the company's employees. This puts Stefano Pessina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Walgreens Boots Alliance own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Walgreens Boots Alliance investors own include AT&T (T), Intel (INTC), CVS Health (CVS), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), AbbVie (ABBV), Verizon Communications (VZ), Pfizer (PFE) and Exxon Mobil (XOM).

Who are Walgreens Boots Alliance's major shareholders?

Walgreens Boots Alliance's stock is owned by a variety of retail and institutional investors. Top institutional investors include Invesco Ltd. (1.97%), Morgan Stanley (1.46%), Northern Trust Corp (0.89%), Legal & General Group Plc (0.77%), Bank of New York Mellon Corp (0.74%) and Charles Schwab Investment Management Inc. (0.68%). Insiders that own company stock include John Patrick Driscoll, Kevin M Ban, Nancy M Schlichting, Richard P Gates, Rosalind G Brewer and Walgreens Boots Alliance, Inc.
View institutional ownership trends
.

How do I buy shares of Walgreens Boots Alliance?

Shares of WBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Walgreens Boots Alliance have any subsidiaries?
The following companies are subsidiares of Walgreens Boots Alliance: Alliance Boots Holdings Limited, Alliance Healthcare Deutschland AG, Bond Drug Company of Illinois LLC, Boots Opticians Professional Services Limited, Boots Properties Limited, Boots Property Partnerships, Boots Retail (Ireland) Limited, Boots Retail (Thailand) Limited, Boots UK Limited, Duane Reade, Farmacias Benavides S.A.B. de C.V., Innovation Associates Inc, Liz Earle Beauty, Prime Therapeutics Specialty Pharmacy LLC, Shields Health Solutions, Sinopharm Holding GuoDa Drug Store Co., Superior Acquisitions Limited, Superior Holdings Limited, Superior Luxco 1 S.à r.l., Take Care Health Employer Solutions, The Boots Company PLC, WBA Acquisitions UK Holdco 7 Limited, WBA Acquisitions UK Topco Limited, WBA Financial LLC, WBA International Limited, WBA Investments Inc., WBA Luxembourg 6 S.à r.l., WBA Luxembourg 7 S.à.r.l., WBAD Holdings Limited, Walgreen Arizona Drug Co., Walgreen Co., Walgreen Eastern Co. Inc., Walgreen International S.à r.l., Walgreen Investments Luxembourg S.à r.l., Walgreen Louisiana Co. Inc., Walgreen of Puerto Rico Inc., Walgreens Boots Alliance (Hong Kong) Investments Limited, Walgreens Boots Alliance Holdings LLC, Walgreens Boots Alliance Limited, Walgreens Specialty Pharmacy LLC, and Waltrust Properties Inc..
Read More
This page (NASDAQ:WBA) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -